New Drug Baxdrostat Could Permanently Cure High Blood Pressure
A breakthrough medication may replace surgery for patients with adrenal gland-related hypertension.
1Breakthrough in Hypertension Treatment
A new medication called baxdrostat has demonstrated potential as a permanent cure for specific cases of high blood pressure. Originally designed to inhibit the hormone aldosterone, the drug unexpectedly kills cells in adrenal gland tumours. This discovery offers a non-surgical alternative for patients whose hypertension is driven by these tiny benign growths.
2Mechanism of Cellular Destruction
Baxdrostat functions by blocking aldosterone production, which triggers the generation of harmful reactive oxygen species within the cells. These compounds effectively destroy the hormone-producing tumour cells located on the adrenal glands. This process mimics the therapeutic benefits currently achieved only through major surgical removal of the affected adrenal gland tissue.
3Clinical Trial Observations
In a study involving 14 patients, participants who took the drug for six to 12 months maintained lower blood pressure levels after stopping treatment. One individual remained off the medication for three years with sustained results. These findings suggest that a finite course of daily pills could provide long-term remission for patients.
4Targeting Stubborn Blood Pressure
The drug is primarily intended for patients whose blood pressure remains dangerously high despite using two or more standard medications. Research indicates that approximately one in ten people with hypertension may have adrenal gland tumours as the underlying cause. These individuals are the primary candidates for this potential new curative treatment approach.
5Regulatory Status and Availability
Baxdrostat received approval in the United States this year for patients with resistant hypertension. In the United Kingdom, the National Institute for Health and Care Excellence is currently evaluating the drug for potential NHS provision. Officials anticipate the treatment could become available to British patients as early as the year 2027.
6Expert Perspectives on Efficacy
Professor Morris Brown of Queen Mary University of London noted that the drug fulfills a long-held ambition to transition from chronic management to a permanent cure. While the initial results are promising, experts emphasize that larger studies are currently underway to confirm the durability of these findings across a broader patient population.
7Impact on Patient Care
The potential shift from invasive adrenal surgery to a daily pill represents a significant advancement in cardiovascular medicine. By targeting the root cause of hormone overproduction, the treatment could benefit over a million people in the UK. This approach reduces the reliance on lifelong medication for a substantial subgroup of hypertensive patients.
8Future Research Directions
Researchers are now focused on gathering longer-term data to substantiate the claim of an infinite cure through a finite medication course. The ongoing larger trial will provide the necessary evidence to validate these extraordinary findings. Future clinical outcomes will determine if this drug becomes a standard protocol for treating adrenal-related hypertension.
Original article: iNews — New Drug Baxdrostat Could Permanently Cure High Blood Pressure